Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

Core Viewpoint - Enzon Pharmaceuticals has initiated an exchange offer for its Series C Non-Convertible Redeemable Preferred Stock in connection with its merger with Viskase Companies, Inc. [1] Offer Details - Enzon is offering holders of Series C Preferred Stock the opportunity to exchange their shares for common stock, with the exchange ratio based on the liquidation preference divided by $7.83, post Reverse Stock Split [2] - The Offer is fully detailed in the Prospectus/Consent Solicitation/Offer to Exchange filed with the SEC on January 28, 2026 [3] Key Dates and Information - The exchange offer commenced on January 30, 2026, and will expire at 11:59 p.m. Eastern Time on February 27, 2026, unless extended [7] - Holders can withdraw their tendered shares at any time before the deadline [7] Company Background - Enzon Pharmaceuticals, Inc. operates as a public company acquisition vehicle, aiming to become an acquisition platform [5] Additional Information - HKL & Co., LLC is the Information Agent for the Offer, while Continental Stock Transfer & Trust Company serves as the Exchange Agent [4] - Investors can access the documents filed with the SEC through the SEC's website or by contacting HKL & Co., LLC [8]